News | October 13, 2021
PCI Pharma Services acquires LSNE for its CDMO business
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
The company plans to raise US $ 15 million
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
Since its inception, the company has either acquired or taken a majority stake in five companies
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site
The drug is being developed at lab scale for the first-line of treatment of Covid-19
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
Subscribe To Our Newsletter & Stay Updated
